After an initial learning curve, the clinical outcomes of patients after TAVR procedures have improved in parallel with a steady decrease in complication rates (3) . This may be explained by the increasing clinical experience of the physicians who perform the implantations, improvements in patient screening using specific imaging strategies (including computed tomography assessment of the target areas), better patient selection that excludes less feasible patients from these therapies, and technical improvements in the individual transcatheter valve prostheses and their application systems (4) (5) (6) (7) (8) .
Despite all of these achievements, TAVR procedures are associated with a considerable remaining risk. Complications such as malposition or displacement of the valve prosthesis, hemodynamic instability requiring cardiocirculatory support, coronary artery occlusions, aortic annular ruptures, aortic dissections, ventricular perforations, arrhythmias, aortic regurgitation, sternotomy, stroke, death, or need for permanent pacemaker implantation have been reported, among others (9, 10) . At present, these risks vary between 3% and 8% depending on the risk profiles of the patients, the overall clinical experience of the teams, and the type of analyses (i.e., whether they are calculated for selected trials or all-comers experiences) (11) (12) (13) (14) (15) . The overall assessment of a relatively new therapeutic procedure like TAVR should be based on population-wide results, which can only be gathered by specific clinical registries. Analysis of such registry data will paint a more realistic picture of the performance and complication rates of a new procedure in the "real world."
Taking these findings into consideration, we analyzed the acute and in-hospital incidence of specific complications associated with TAVR procedures from the all-comers German Aortic Valve Registry (GARY).
We specifically focused on the potential for a decrease in complications over time due to a learning curve effect and on the potentially predictive risk factors that could be associated with specific complications.
METHODS
GARY was designed as an all-comers registry for patients treated for aortic valve disease from July 2010 to 2015. Details have been reported previously (16) (17) (18) . All-comers data from 88 sites are included in this registry. All contributing sites had sufficient previous clinical experience with TAVR procedures.
In total, 4% of the procedures were performed at sites without a department of cardiac surgery but with a cardiac surgeon on standby.
Registry data, derived in part from the mandatory quality control, were carefully entered into the database and then checked for completeness and consistency. Thereafter, the database was finalized for the analysis. All further calculations were compiled at an independent medical research institution, the BQS Table 2 . A total of 792 patients (5%) experienced at least 1 SVC ( Tables 1 and 2 ). These 792 patients were 81 AE 6 years old, 59.5% were women, the logistic Euroscore Table 1) . Patients with SVCs also had a significantly higher incidence of these CPB ¼ cardiopulmonary bypass; other abbreviations as in Table 1 . Values are n (%).
Abbreviations as in Table 1 .
procedural parameters: nonelective procedures;
use of general anesthesia; use of cardiopulmonary bypass; conversion to open heart surgery; tamponade; vascular complications; residual aortic regurgitation $2 ; prolonged procedural duration; and longer radiation time ( Table 2) .
In univariate and multivariate logistic regression analyses, female sex, NYHA functional class IV, EF #30%, the need for preoperative inotropic medication, peripheral vascular disease, a higher degree of aortic valve calcification, and aortic stenosis of 4 were independent predictors of the occurrence of SVCs ( Table 5) . Patients who experienced TCOs were significantly different from all other patients concerning these variables; they were less frequently women; had a higher logistic Euroscore and a higher German AV score; had a higher incidence of previous cardiac surgery; more frequently had an EF <30%; were more frequently on ventilators; more frequently received inotrope therapy; had lower mean and maximum pressure gradients; had lower degree of calcifications; and more frequently exhibited grade 4 aortic stenosis and aortic regurgitation ( Table 1) . Periprocedural results revealed that patients with TCOs had significantly higher rates of cardiopulmonary bypass, conversion to open heart surgery, tamponade, intraprocedural vascular complications, residual aortic regurgitation $2 , longer duration of the procedure, increased radiation time, and increased contrast dye use ( Table 2) . They also had significantly lower rates of balloon dilation and rapid pacing for implantation.
Technical complications occurred in 748 patients
In the multivariate assessment, independent predictors for TCOs were male sex, EF <30%, neurological dysfunction, cardiac decompensation, and intravenous inotrope therapy ( Table 5 ). In addition, a learning curve was apparent because the incidence of TCOs decreased over the years ( Table 3) . Table 2) , with a significant decline from 30.6% Tables 1 and 4 . Table 3) .
Patients who required sternotomy presented with a significantly higher incidence of a high German AV score and receipt of intravenous inotropic therapy and had a significantly lower incidence of a porcelain aorta ( Table 1) . They underwent elective procedures less frequently; were treated with general anesthesia more frequently; had a higher use of cardiopulmonary bypass; more frequently experienced tamponade, intraprocedural vascular complications, and aortic regurgitation $2
; and had longer procedural duration and radiation time (all p < 0.05) ( Table 2) .
Survival of patients who required conversion to sternotomy was 57.7% (n ¼ 116/201).
Univariate and multivariate analyses of these data excluded any predictors for the potential occurrence of sternotomy during a TAVR procedure.
Stroke occurred in a total of 1.5% (242/15,964) of the patients ( Table 2) . It was significantly more frequent in patients who experienced SVCs (4.2%; p < 0.001), in patients with TCOs (4.1%; p < 0.001), in patients who required sternotomy (3.5%; p ¼ 0.034), and in patients who died (6.3%; p < 0.001). In addition, the 1.3% incidence of conversion to sternotomy was acceptably low without any significant changes over the years. Predictors for this complication were not identified, despite a very large number of patients. Finally, the overall in-hospital death rate of 5.2% was acceptable and did not change significantly over the years examined. Twenty independent predictors for death were determined, as summarized in Table 3 .
SVC, TCO, AND OTHER COMPLICATIONS. SVCs during TAVR procedures included major challenges for the entire heart team involved in treating these patients. Therefore, it was encouraging to observe that there was a significant decrease in SVCs over the years. However, the current incidence of these complications is still appreciable and remains at approximately 4%, despite the large clinical experience that is available throughout Germany at many specific sites that perform TAVR procedures.
Based on these numbers, we suggest that TAVR should remain a heart team-led procedure performed by anesthesiologists, cardiologists, and cardiac surgeons. The continuing use of experienced heart teams, together with optimal infrastructure and standard operating processes, will be the only way forward to further minimize and eventually manage such complications. (27, 28) . The incidence of new-onset pacemaker implantation of 17.5% was rather high, and was shown to be associated with TAVR and with the choice of prosthetic valve to be implanted (29) . However, for the acute performance of the procedures, we believe that this is only of minor importance.
SURVIVAL AFTER COMPLICATIONS. Overall survival rates were 59.2% (SVCs), 82.9% (TCOs), and 57.7% (sternotomy). In view of some significant complications that were present especially in the SVC, TCO, and sternotomy groups, these survival rates were quite encouraging. Without direct heart team therapy on site, some of these patients might have died; therefore, to decrease complications and optimize outcomes TAVR should be performed by an established heart team with an appropriate infrastructure.
STUDY LIMITATIONS. There were several limitations to the present study, and these were especially related to the nature of a registry: all-comers data could only be captured by a registry, but such data might lack some of the details as well as the correlated adjudication that a randomized trial might have.
CONCLUSIONS
In the all-comers GARY registry, patients attained good outcomes after TAVR and experienced a regression in complications over time. SVCs and TCOs of TAVR procedures remained at 4%, need for sternotomy remained at 1.2% without any predictors, and the in-hospital death rate remained at 5% in this high- 
